EORTC, CTI, and IRROG collaboration opens new opportunities in Ireland
12 Dec 2022
Promising results for the ultra-low risk patient group in latest MINDACT analysis
27 Jan 2022
PRESS RELEASE: Sanofi partnering with leading academic cooperative groups to study amcenestrant in the adjuvant setting for patients with estrogen receptor positive breast cancer
4 Jun 2021
Long-term results from MINDACT trial confirm importance of gene expression signature in choosing breast cancer patients who can be spared chemotherapy
13 Mar 2021
15 year follow up of EORTC 22922/10925 phase III trial shows reduction in breast cancer mortality and recurrence but does not confirm improved overall survival
18 Nov 2020
EORTC abstracts selected at EBCC-12 Virtual Congress
28 Sep 2020
MINDACT (EORTC 10041/BIG3-04): Long-term results of the large prospective trial testing the 70-gene signature MammaPrint as guidance for adjuvant chemotherapy in breast cancer patients
29 May 2020
EBCC12: Conference postponed until 30 Sept – 2 October 2020, in Barcelona Spain
6 Mar 2020